T1	Participants 60 113	patients with unresectable HCC and in HCC cell lines.
T2	Participants 259 271	HCC patients
T3	Participants 342 402	HCC patients who had both elevated AFP and DCP were included
T4	Participants 491 517	27-patient phase II cohort
